Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | TYMS | P04818 | 2/20 | 0.38 |
| ▸ | TYMP | P19971 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7070893 | 0.78 | DHFR (0.47) | KDM4ETYMSTYMPALDH1A1DHFR | |
| SCHEMBL8080258 | 0.69 | ALDH1A1 (0.36) | KDM4ETYMSTYMPALDH1A1DHFR | |
| SCHEMBL7215330 | 0.68 | ALDH1A1 (0.43) | KDM4ETYMSALDH1A1GAACYP2C9 | |
| SCHEMBL24625402 | 0.66 | ALDH1A1 (0.47) | KDM4ETYMSALDH1A1DHFRPOLB | |
| SCHEMBL3952293 | 0.66 | ALDH1A1 (0.50) | KDM4EALDH1A1GAALMNA | |
| SCHEMBL10853896 | 0.64 | TYMP (0.56) | KDM4ETYMPALDH1A1GAAXDH | |
| SCHEMBL9597919 | 0.64 | TYMP (0.38) | KDM4ETYMPALDH1A1POLBGAA | |
| SCHEMBL20661646 | 0.63 | ALDH1A1 (0.49) | KDM4ETYMSALDH1A1DHFRPOLB | |
| SCHEMBL6839969 | 0.63 | MAOA (0.40) | KDM4ETYMPALDH1A1GAAHPGD | |
| Diphenylsulfane SCHEMBL28818235 | 0.63 | HPGD (0.56) | KDM4EALDH1A1HPGDHSD17B10MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5225550-A | PROCESS FOR THE PREPARATION OF SUBSTITUTED ACYCLIC NUCLEOSIDES, AND INTERMEDIATES OCCURRING THEREIN | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-07-06 | — | — | US | claimed |
| EP-0464511-A2 | Process for the preparation of acyclic, substituted nucleosides and its intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-01-08 | — | — | EP | claimed |
| US-12048748-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| CN-117736134-A | Compounds and methods for enhancing degradation of target proteins and other polypeptides by E3 ubiquitin ligases | 耶鲁大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-116670161-A | Methods of preventing or treating viral-induced organ injury or failure using IL-22 dimers | 亿一生物医药开发(上海)有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230095223-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| CN-114469958-A | Method for prophylactic treatment of viruses and pre-exposure prophylactic kit | 艾利安有限责任公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-1343502-A2 | METHODS FOR INHIBITING THE TRANSMISSION OF HIV USING TOPICALLY APPLIED SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES | Idenix (Cayman) Limited (KY) | 2003-09-17 | — | — | EP | disclosed |
| US-RE37979-E1 | Pyrimidine derivatives and anti-viral agent containing the same as active ingredient thereof | MITSUBISHI CHEMICAL CORPORATION | 2003-02-04 | — | — | US | disclosed |
| EP-0829476-B1 | 6-Substituted acyclopyrimidine nucleoside derivatives and antiviral agent containing the same as active ingredient thereof | MITSUBISHI CHEM CORP (JP) | 2002-08-28 | — | — | EP | disclosed |
| WO-2002040021-A2 | METHODS FOR INHIBITING THE TRANSMISSION OF HIV USING TOPICALLY APPLIED SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES | IDENIX (CAYMAN) LIMITED (KY) | 2002-05-23 | — | — | WO | disclosed |
| EP-0829476-A2 | 6-Substituted acyclopyrimidine nucleoside derivatives and antiviral agent containing the same as active ingredient thereof | Mitsubishi Chemical Corporation (JP) | 1998-03-18 | — | — | EP | disclosed |
| US-5461060-A | Antiretroviral activity | MITSUBISHI KASEI CORPORATION (JP) | 1995-10-24 | — | — | US | disclosed |
| US-5225550-A | PROCESS FOR THE PREPARATION OF SUBSTITUTED ACYCLIC NUCLEOSIDES, AND INTERMEDIATES OCCURRING THEREIN | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-07-06 | — | — | US | disclosed |
| EP-0464511-A2 | Process for the preparation of acyclic, substituted nucleosides and its intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-01-08 | — | — | EP | disclosed |
| EP-0420763-A2 | 6-Substituted acyclopyrimidine nucleoside derivatives and antiviral agent containing the same as active ingredient thereof | Mitsubishi Chemical Corporation (JP) | 1991-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230095223-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | KDM4E 1930/4885TYMS 3186/4885TYMP 4409/4885 |
| US-12048748-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | KDM4E 1930/4885TYMS 3186/4885TYMP 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.